(Q27016157)

J. Menard

series ordinal

3

1 reference

language of work or name

1 reference

January 2013

1 reference

Nephrology Dialysis Transplantation

published in

1 reference

volume

28

1 reference

issue

1

1 reference

page(s)

36-43

1 reference

Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents.

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone and end-organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Renal damage in primary aldosteronism: results of the PAPY Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Serum aldosterone and the incidence of hypertension in nonhypertensive persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Hyperaldosteronism among black and white subjects with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Body mass index predicts aldosterone production in normotensive adults on a high-salt diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone production and insulin resistance in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Mechanisms of mineralocorticoid action

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The regulation of aldosterone synthase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effects of aldosterone on the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The role of aldosterone in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Human aldosterone synthase: recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The human steroid hydroxylases CYP1B1 and CYP11B2

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Acute and chronic regulation of aldosterone production

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Expression profiles for steroidogenic enzymes in adrenocortical disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The 45-year story of the development of an anti-aldosterone more specific than spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone-receptor antagonism in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone in the development and progression of renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

A review of the medical treatment of primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Efficacy and tolerance of spironolactone in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Investigation of aldosterone-synthase inhibition in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

Body Elemental Composition, with Particular Reference to Total and Exchangeable Sodium and Potassium and Total Chlorine, in Untreated and Treated Primary Hyperaldosteronism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFS388

release_gyhobuocingqlc437i3mjhtofi

21 January 2018

Identifiers

DOI

10.1093/NDT/GFS388

0 references

Fatcat ID

0 references

PubMed publication ID

23045428

1 reference